Annovis Bio Inc. - notizie pubblicate 175 - letture 3.725
ANNOVIS BIO INC.
Quarterly Report for Quarter Ending June 30, 2023 (Form 10-Q)
Table of contents united states securities and exchange commission washington, d.c. 20549 form 10-q ☒ quarterly report pursuant to section 13 or 15(d) of the securities exchange ...
ANNOVIS BIO INC.
July 18, 2023Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
Tue, 18 jul 2023 berwyn, pa.--(business wire)-- annovis bio, inc. (nyse: anvs), a late-stage clinical drug platform company developing transformative therapies to treat neurodegene ...
ANNOVIS BIO INC.
June 27, 2023Annovis Bio Announces the Filing of a Groundbreaking Patent
Tue, 27 jun 2023 the composition of matter patent is the single most important patent for any pharmaceutical company developing a new drug berwyn, pa.--(business wire)-- annovis bi ...
ANNOVIS BIO INC.
June 20, 2023Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
Tue, 20 jun 2023 the drug is proving to be safe and well-tolerated berwyn, pa.--(business wire)-- annovis bio, inc. (nyse: anvs), announces the positive safety review by the data a ...
ANNOVIS BIO INC.
Certificate of Incorporation/Bylaws - Form 8-K
United states securities and exchange commission washington, dc 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report ...
ANNOVIS BIO INC.
June 8, 2023Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace
Thu, 08 jun 2023 berwyn, pa., june 8, 2023/prnewswire/ -- annovis bio, inc. (nyse: anvs), a clinical-stage drug platform company addressing neurodegenerative diseases such as alzhe ...
ANNOVIS BIO INC.
Additional Proxy Soliciting Materials - Form DEFA14A
United states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1934 filed by the r ...
ANNOVIS BIO INC.
Change in Certifying Accountants - Form 8-K
United states securities and exchange commission washington, dc 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report ...
ANNOVIS BIO INC.
May 11, 2023Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
Thu, 11 may 2023 berwyn, pa., may 11, 2023 (globe newswire) -- annovis bio, inc. (nyse: anvs) ("annovis" or the "company"), a clinical-stage drug platform compa ...
ANNOVIS BIO INC.
Quarterly Report for Quarter Ending March 31, 2023 (Form 10-Q)
Table of contents united states securities and exchange commission washington, d.c. 20549 form 10-q ☒ quarterly report pursuant to section 13 or 15(d) of the securities exchange ...
ANNOVIS BIO INC.
Proxy Statement - Form DEF 14A
United states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1934 (amendment no. ...
ANNOVIS BIO INC.
Annual Report - Form ARS
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer annovis bio inc. pub ...
ANNOVIS BIO INC.
April 27, 2023Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
Thu, 27 apr 2023 berwyn, pa., april 27, 2023 (globe newswire) -- (nyse: anvs) ("annovis" or the "company"), a clinical-stage drug platform company developing tr ...
ANNOVIS BIO INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ANNOVIS BIO INC.
Notice of Sales of Unregistered Securities - Form
The securities and exchange commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. the reader should not assu ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti